Tocilizumab and rituximab reduce relapse rates and disability progression in NMOSD, with tocilizumab provides extra benefits in MOGAD.

Siltuximab effectively treated patients who experienced common adverse events after chimeric antigen receptor T-cell therapy, ...

Purpose: The pharmacology, pharmacokinetics, clinical efficacy, safety, and role of tocilizumab in rheumatoid arthritis (RA) are reviewed. Summary: Tocilizumab is a novel monoclonal antibody that ...

The US Food and Drug Administration (FDA) has granted approval for Celltrion's Avtozma (tocilizumab-anoh) in both intravenous and subcutaneous formulations as an Actemra biosimilar for treating ...

Findings showed tocilizumab-anoh had comparable efficacy, pharmacokinetics, safety, and immunogenicity with Actemra. The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab ...

Avtozma, which is Celltrion’s twelfth biosimilar to be approved by the EC, is a recombinant humanised monoclonal antibody designed to inhibit soluble and membrane-bound interleukin‑6 receptors ...

AVTOZMA® is Celltrion’s twelfth biosimilar to obtain marketing authorization in the European Union. Stay tuned to Big Molecule Watch for more regulatory updates on biosimilars.

The biosimilar of IL-6 inhibitor tocilizumab, called Tyenne (formerly MSB11456), has been approved for the same indications as Roche’s brand, including rheumatoid arthritis, systemic juvenile ...

Celltrion today announced that the European Commission (EC) has granted marketing authorization for Avtozma® (CT-P47), a biosimilar referencing RoActemra® (tocilizumab). Avtozma® has been approved for ...

Celltrion announced on the 24th that it has received product approval from the European Commission (EC) for ACTEMRA (ingredient name tocilizumab), a biosimilar for the treatment of autoimmune diseases ...

Reason for decision Not eligible for Health Technology Evaluation guidance Further information Decision makers have concluded that this technology will not progress as a potential technology appraisal ...